NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Pharmacokinetics (pK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC) vs chewable tablet formulation in patients (pts) on chronic methadone therapy.

Friedland G, Rainey P, Jatlow P, Andrews L, Damle B, McCance-Katz E; International Conference on AIDS.

Int Conf AIDS. 2002 Jul 7-12; 14: abstract no. TuPeB4548.

Yale University School of Medicine, New Haven CT, United States

BACKGROUND: PK interactions between HIV and substance abuse therapies may alter the distribution and efficacy / toxicity profile of each or both. Methadone alters gastric motility and may decrease bioavailability of co-administered drugs. In a previous study, pts receiving methadone with the tablet formulation of ddI (200 mg BID) were shown to have decreased ddI bioavailability. OBJECTIVE: To evaluate the relative bioavailability of ddI from encapsulated enteric coated bead formulation (EC) relative to chewable/dispersible tablet formulation in pts on chronic methadone treatment.. METHODS: A single dose 2-way crossover study in HIV negative pts on stable methadone dose. Pts randomized to EC or tablet formulation (400mg po QD) on day 1 and 2 with methadone dose and pK monitoring over 24 hrs. Alternative regimen given on day 3 and 4 with repeat pK monitoring. Toxicology screen at baseline and daily. Lab and clinical parameters followed for toxicity and opiate withdrawal. Comparisons made to historical data in non-methadone pts receiving ddI. RESULTS: Of 18 patients enrolled, 17 had evaluable data, 15 with both treatments, 1 withdrawn for non-methadone opiate detection. Pt characteristics: female (5), White (15), Hispanic (2), mean age 38 yrs; median weight 175 lbs, median methadone dose/duration, 71 mg/17 mos. CONCLUSION: This study indicates increased bioavailability from EC compared to tablet formulation in patients receiving chronic methadone treatment; there is a trend toward lowering of systemic exposure of ddI after dosing with the tablet in methadone-treated patients, consistent with previous study. EC provided plasma AUC levels comparable to historical controls in non-methadone patients. These data indicate that EC formulation of ddI can be administered to pts receiving methadone.[table: see text]

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • Area Under Curve
  • Biological Availability
  • Chemistry, Pharmaceutical
  • Cross-Over Studies
  • Didanosine
  • Drug Interactions
  • Female
  • HIV Infections
  • Humans
  • Methadone
  • Narcotics
  • Physical Therapy Modalities
  • pharmacokinetics
  • therapy
Other ID:
  • GWAIDS0014328
UI: 102251826

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov